Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients

Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could inform real-world risk-stratified post-ASCT strategies. We investigated the impact of double hit genetics (≥2 adverse markers: t(4;14), t(14;16...

Full description

Bibliographic Details
Main Authors:	Aikaterini Panopoulou, Sandra Easdale, Mark Ethell, Emma Nicholson, Mike Potter, Asterios Giotas, Helena Woods, Tracy Thornton, Charlotte Pawlyn, Kevin D. Boyd, Martin F. Kaiser
Format:	Article
Language:	English
Published:	Wiley 2023-02-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000831

Similar Items

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialResearch in context
by: John R. Jones, et al.
Published: (2023-08-01)

Molecular profiling in myeloma
by: Charlotte Pawlyn, et al.
Published: (2018-06-01)

Induction Treatment in Transplant-eligible Multiple Myeloma
by: J. Quinn, et al.
Published: (2021-05-01)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
by: Arthur Bobin, et al.
Published: (2020-05-01)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
by: Roger Owen, et al.
Published: (2022-06-01)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
by: Sarah A. Bird, et al.
Published: (2020-05-01)

How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
by: Shah, V, et al.
Published: (2020)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020-12-01)

Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
by: Qerimi V, et al.
Published: (2018-06-01)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
by: E. Crusoe, et al.
Published: (2022-06-01)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
by: Aurelia Chacon, et al.
Published: (2023-03-01)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Tereza Popková, et al.
Published: (2023-08-01)

PB2109: PROGNOSTIC VALUE OF MYC STRUCTURAL VARIATIONS IDENTIFIED BY FISH IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Ines Dos Santos Marques, et al.
Published: (2023-08-01)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
by: Ajay K. Nooka, et al.
Published: (2022-04-01)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
by: Rodrigo Fonseca, et al.
Published: (2023-03-01)

Ultra-Micro Lending Eligibility Support System With Exponential Comparison Method (MPE)
by: Ninuk Wiliani, et al.
Published: (2023-06-01)

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
by: Anu Partanen, et al.
Published: (2024-02-01)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
by: Rodrigo Fonseca, et al.
Published: (2023-05-01)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
by: Stefania Oliva, et al.
Published: (2021-06-01)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
by: M. Christine Bennink, et al.
Published: (2022-07-01)

PB1992: HISPANIC ETHNICITY AS A STRONG PREDICTOR OF POOR RESPONSE TO INDUCTION THERAPY AND ASCT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: I. Chineke, et al.
Published: (2022-06-01)

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
by: Chim Chor
Published: (2010-11-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA
by: P. Malandrakis, et al.
Published: (2023-05-01)

HOW PUBLIC POLICIES HAVE IMPROVED THE OVERALL SURVIVAL OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS IN THE CHILEAN PUBLIC HEALTH SYSTEM
by: E Galindo, et al.
Published: (2023-10-01)

EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
by: A Santos, et al.
Published: (2021-10-01)

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS
by: EQ Crusoe, et al.
Published: (2021-10-01)

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
by: C. Cerchione, et al.
Published: (2022-06-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
by: E.Q. Crusoé, et al.
Published: (2020-11-01)

Is Eligible to Be Indexed in MEDLINE?
by: Sun Huh
Published: (2018-12-01)

An Eligible Bachelor: Austen, Love, and Marriage in 'Pride and Prejudice' and 'Eligible' by Curtis Sittenfeld
by: Carmen Gomez-Galisteo
Published: (2022-10-01)

P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY.
by: F Fazio, et al.
Published: (2022-04-01)

P902: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY
by: F. Fazio, et al.
Published: (2022-06-01)

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
by: Amelie Boquoi, et al.
Published: (2022-04-01)

Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
by: Rafiye Çiftçiler, et al.
Published: (2021-02-01)

Eligibility for renal transplantation: A Moroccan interregional survey
by: Nadia Kabbali, et al.
Published: (2015-01-01)

IMPACT OF DARATUMUMAB (DARA) ADMINISTRATION DURING TRANSPLANT- ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) INDUCTION ON STEM CELL (SC) MOBILIZATION COUNT AND POST-TRANSPLANT ENGRAFTMENT
by: EQ Crusoe, et al.
Published: (2021-10-01)

Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients
by: Ahmed Kotb Abdrabou, et al.
Published: (2024-03-01)